Tuebingen

• An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat … Recruiting
  2024-519913-76-00 4 2025-12-09 PDL1-negative metastatic triple-negative breast cancer
• A Study to Investigate the Safety, Tolerability, and Exposure of Single Doses of the study medicine STK-002, in Patients with Autosomal Domi … Recruiting
  2023-506290-35-00 1 2025-12-08 Autosomal Dominant Optic Atrophy
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting
  2024-517261-16-00 9 2025-12-05 Advanced solid tumors
• Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 Recruiting
  2024-514763-25-01 1 2025-12-04 spinocerebellar ataxia type 2
• A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting
  2024-512577-27-00 5 2025-12-02 Chronic kidney disease in paediatric patients
• DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for … Recruiting
  2025-521644-37-00 4 2025-11-28 locally advanced or metastatic penile squamous cell carcinoma
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting
  2025-521242-26-00 4 2025-11-27 Moderately to Severely Active Ulcerative Colitis
• Antimalarial prophylactic efficacy of a weekly dose atovaquone-proguanil Recruiting
  2024-518884-36-00 4 2025-11-12 Malaria
• A Study to Compare Vusolimogene oderparepvec (VO) Plus Nivolumab With the Doctor's Choice of Treatment in People With Skin Cancer That has G … Recruiting
  2023-508612-29-00 5 2025-11-07 Advanced Melanoma
• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting
  2025-521260-35-00 6 2025-11-07 acute ischemic stroke and atrial fibrillation (AF)
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P … Recruiting
  2024-517131-52-00 5 2025-11-03 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
• A study to investigate the efficacy and safety of SAR444336 in adults with microscopic colitis in clinical remission. Recruiting
  2024-519495-83-00 4 2025-10-28 Digestive system diseases
• INITIATE-LECIG: Intestinal levodopa + entacapone therapy (Lecigon®) to counteract dopaminergic desensitization and neuropsychiatric complica … Recruiting
  2025-521048-39-00 5 2025-10-28 Parkinson Disease
• Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy. Recruiting
  2025-521640-38-00 5 2025-10-16 Focal onset seizures or primary generalized tonic-clonic seizures.
• A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell … Recruiting
  2024-516234-35-00 9 2025-10-15 Relapsed or Refractory B-Cell Malignancies
• Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD- … Recruiting
  2024-520264-33-00 5 2025-10-07 Locoregionally recurrent head and neck squamous cell carcinoma (HNSCC)
• Long-term follow-up of patients treated with GD2IL18CART Recruiting
  2025-521497-34-00 1 2025-10-06 Neuroblastoma
• A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors pr … Recruiting
  2024-512403-39-01 1 2025-10-03 Advanced Solid Tumors Who Are Beyond Standard of Care
• Using lab-grown mini-tumors from pancreatic cancer tissue to predict and improve post-surgery treatment for pancreatic cancer Recruiting
  2023-510490-34-00 4 2025-09-29 Patients with functionally resectable pancreatic ductal adenocarcinoma
• A Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retiniti … Recruiting
  2024-515199-10-01 4 2025-09-29 Retinitis Pigmentosa
• CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer Recruiting
  2024-517190-24-00 4 2025-09-16 Peritoneal Cancer

Showing 121–144 of 591 trials